Advocacy intelligence hub — real-time data for patient organizations
Amgen — PHASE2
Acepodia Biotech, Inc. — PHASE1, PHASE2
Changhai Hospital — EARLY_PHASE1
Stanford University — PHASE2
Sanofi — PHASE3
Chinese PLA General Hospital — PHASE2
Peking Union Medical College Hospital — PHASE2, PHASE3
Luo Yaping — NA
IRCCS San Raffaele
Peking University Third Hospital
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Uplizna
Horizon Therapeutics USA, Inc.
Leustatin Injection
R. W. Johnson Pharmaceutical Research Institute
Uplizna
(INEBILIZUMAB)Orphan drugstandardHorizon Therapeutics USA, Inc.
CD19-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action The mechanism by which inebilizumab-cdon exerts its therapeutic effects in NMOSD, IgG4-RD, and gMG is presumed to involve bin...
Zhanguo Li
Peking University Institute of Rheuamotology and Immunology
Wen Zhang, MD
Deptment of Rheumatology, Peking Union Medical College Hospital
John H Stone, MD
Massachusetts General Hospital and Harvard Medical School
Lingli Dong
Tongji Hospital
Lingli Dong, MD
Tongji Hospital
John H. Stone, MD, MPH
Johns Hopkins University